

# HOUSE BILL 33

E1

(PRE-FILED)

2lr1215  
CF SB 614

---

By: **Delegate Shetty**

Requested: November 1, 2021

Introduced and read first time: January 12, 2022

Assigned to: Judiciary

---

Committee Report: Favorable

House action: Adopted

Read second time: March 7, 2022

---

## CHAPTER \_\_\_\_\_

1 AN ACT concerning

2 **Criminal Law – Controlled Dangerous Substances – Schedules – Adjustment**

3 FOR the purpose of repealing certain lists of substances designated as controlled dangerous  
4 substances under certain schedules under the Maryland Controlled Substances Act;  
5 and generally relating to schedules of controlled dangerous substances.

6 BY repealing and reenacting, with amendments,

7 Article – Criminal Law

8 Section 5–101(z) through (dd) and 5–402 through 5–406

9 Annotated Code of Maryland

10 (2021 Replacement Volume and 2021 Supplement)

11 BY repealing and reenacting, without amendments,

12 Article – Criminal Law

13 Section 5–202(a), (b), and (f)

14 Annotated Code of Maryland

15 (2021 Replacement Volume and 2021 Supplement)

16 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,  
17 That the Laws of Maryland read as follows:

18 **Article – Criminal Law**

19 5–101.

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

Underlining indicates amendments to bill.

~~Strike out~~ indicates matter stricken from the bill by amendment or deleted from the law by amendment.



1 (z) “Schedule I” means [a list of] **THE** controlled dangerous substances [that  
2 appears] **DESCRIBED** in § 5–402 of this title.

3 (aa) “Schedule II” means [a list of] **THE** controlled dangerous substances [that  
4 appears] **DESCRIBED** in § 5–403 of this title.

5 (bb) “Schedule III” means [a list of] **THE** controlled dangerous substances [that  
6 appears] **DESCRIBED** in § 5–404 of this title.

7 (cc) “Schedule IV” means [a list of] **THE** controlled dangerous substances [that  
8 appears] **DESCRIBED** in § 5–405 of this title.

9 (dd) “Schedule V” means [a list of] **THE** controlled dangerous substances [that  
10 appears] **DESCRIBED** in § 5–406 of this title.

11 5–202.

12 (a) The Department shall control all substances listed in Subtitle 4 of this title.

13 (b) In accordance with the Administrative Procedure Act, the Department may  
14 add a substance as a controlled dangerous substance on its own initiative or on the petition  
15 of an interested party.

16 (f) (1) A new substance that is designated as a controlled substance under  
17 federal law is a similarly controlled dangerous substance under this title unless the  
18 Department objects to the inclusion.

19 (2) If the Department objects, it shall publish the reasons for the objection  
20 and give each interested party an opportunity to be heard.

21 (3) After the hearing, the Department shall publish its decision, which is  
22 final.

23 (4) An action for judicial review of a final decision made in accordance with  
24 this section does not stay the effect of the decision.

25 5–402.

26 (a) Schedule I consists of each [controlled dangerous substance]:

27 (1) [listed in] **CONTROLLED DANGEROUS SUBSTANCE ANALOGUE, AS**  
28 **DEFINED IN SUBSECTION (B) OF** this section;

29 (2) **CONTROLLED DANGEROUS SUBSTANCE** added to Schedule I by the  
30 Department under § 5–202(b) of this title; [or] **AND**

1 (3) **CONTROLLED DANGEROUS SUBSTANCE** designated as a Schedule I  
2 controlled dangerous substance by the federal government unless the Department objects  
3 under § 5–202(f) of this title.

4 [(b) Unless specifically excepted under this subtitle or listed in another schedule,  
5 any of the following opiates, including their isomers, including optical and geometric  
6 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the  
7 existence of such isomers, esters, ethers, or salts is possible within the specific chemical  
8 designation, are substances listed in Schedule I:

9 (1) acetyl- $\alpha$ -methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-  
10 piperidiny]-N-phenylacetamide);

11 (2) acetylmethadol;

12 (3) acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

13 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide);

14 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl])  
15 benzamide;

16 (6) allylprodine;

17 (7) alphacetylmethadol, except levo-alphacetylmethadol;

18 (8) alphameprodine;

19 (9) alphamethadol;

20 (10)  $\alpha$ -methylfentanyl (N-[1-( $\alpha$ -methyl- $\beta$ -phenyl)ethyl-4-  
21 piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

22 (11)  $\alpha$ -methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-  
23 piperidiny]-N-phenylpropanamide);

24 (12) benzethidine;

25 (13) betacetylmethadol;

26 (14)  $\beta$ -hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-  
27 piperidiny]-N-phenylpropanamide);

28 (15)  $\beta$ -hydroxy-3-methylfentanyl;

- 1 (16) N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-  
2 phenylpropionamide;
- 3 (17) betameprodine;
- 4 (18) betamethadol;
- 5 (19) betaprodine;
- 6 (20) butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
7 phenylbutyramide);
- 8 (21) clonitazene;
- 9 (22) dextromoramide;
- 10 (23) diampromide;
- 11 (24) diethylthiambutene;
- 12 (25) difenoxin;
- 13 (26) dimenoxadol;
- 14 (27) dimepheptanol;
- 15 (28) dimethylthiambutene;
- 16 (29) dioxaphetyl butyrate;
- 17 (30) dipipanone;
- 18 (31) ethylmethylthiambutene;
- 19 (32) etonitazene;
- 20 (33) etoxeridine;
- 21 (34) 4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-  
22 phenethylpiperidin-4-yl)isobutyramide);
- 23 (35) furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-  
24 carboxamide);
- 25 (36) furethidine;
- 26 (37) hydroxypethidine;

- 1 (38) ketobemidone;
- 2 (39) levomoramide;
- 3 (40) levophenacymorphan;
- 4 (41) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-  
5 phenylpropanamide);
- 6 (42) 3-methylthiofentanyl;
- 7 (43) morpheridine;
- 8 (44) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
- 9 (45) mt-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);
- 10 (46) noracymethadol;
- 11 (47) norlevorphanol;
- 12 (48) normethadone;
- 13 (49) norpipanone;
- 14 (50) ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-  
15 4-yl)acetamide);
- 16 (51) para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-  
17 piperidiny] propanamide);
- 18 (52) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 19 (53) phenadoxone;
- 20 (54) phenampromide;
- 21 (55) phenomorphan;
- 22 (56) phenoperidine;
- 23 (57) piritramide;
- 24 (58) proheptazine;
- 25 (59) properidine;

- 1 (60) propiram;
- 2 (61) racemoramide;
- 3 (62) tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
4 phenyltetrahydrofuran-2-carboxamide);
- 5 (63) thiofentanyl;
- 6 (64) tilidine;
- 7 (65) trimeperidine; and
- 8 (66) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-  
9 methylbenzamide).

10 (c) Unless specifically excepted under this subtitle or listed in another schedule,  
11 any of the following opium derivatives, including their salts, isomers, and salts of isomers,  
12 whenever the existence of such salts, isomers, or salts of isomers is possible within the  
13 specific chemical designation, are substances listed in Schedule I:

- 14 (1) acetorphine;
- 15 (2) acetyldihydrocodeine;
- 16 (3) benzylmorphine;
- 17 (4) codeine methylbromide;
- 18 (5) codeine-N-oxide;
- 19 (6) cyprenorphine;
- 20 (7) desomorphine;
- 21 (8) dihydromorphine;
- 22 (9) drotebanol;
- 23 (10) etorphine (except hydrochloride salt);
- 24 (11) heroin;
- 25 (12) hydromorphanol;
- 26 (13) methyl-desorphine;

- 1 (14) methyldihydromorphine;
- 2 (15) morphine methylbromide;
- 3 (16) morphine methylsulfonate;
- 4 (17) morphine-N-oxide;
- 5 (18) myrophine;
- 6 (19) nicocodeine;
- 7 (20) nicomorphine;
- 8 (21) normorphine;
- 9 (22) pholcodine; and
- 10 (23) thebacon.

11 (d) Unless specifically excepted under this subtitle or listed in another schedule,  
12 any material, compound, mixture, or preparation that contains any quantity of the  
13 following hallucinogenic substances, or that contains any of its salts, isomers, including  
14 optical, position, and geometric isomers, or salts of isomers, whenever the existence of such  
15 salts, isomers, or salts of isomers is possible within the specific chemical designation, is a  
16 substance listed in Schedule I:

- 17 (1) alpha-ethyltryptamine;
- 18 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 19 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 20 (4) 2,5-dimethoxyamphetamine;
- 21 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 22 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7);
- 23 (7) 4-methoxyamphetamine (PMA);
- 24 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 25 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 26 (10) 3,4-methylenedioxy amphetamine;

- 1 (11) 3,4-methylenedioxyamphetamine (MDMA);
- 2 (12) 3,4-methylenedioxy-N-ethylamphetamine (MDA);
- 3 (13) N-hydroxy-3,4-methylenedioxyamphetamine;
- 4 (14) 3,4,5-trimethoxyamphetamine;
- 5 (15) 5-methoxy-N, N-dimethyltryptamine;
- 6 (16) alpha-methyltryptamine (AMT);
- 7 (17) bufotenine;
- 8 (18) diethyltryptamine (DET);
- 9 (19) dimethyltryptamine (DMT);
- 10 (20) 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT);
- 11 (21) ibogaine;
- 12 (22) lysergic acid diethylamide;
- 13 (23) marijuana;
- 14 (24) mescaline;
- 15 (25) parahexyl-7374;
- 16 (26) peyote (meaning all parts of the plant presently classified botanically  
17 as *Lophophora williamsii* lemaire, whether growing or not, the seeds thereof, any extract  
18 from any part of such plant, and every compound, manufacture, salt, derivative, mixture,  
19 or preparation of such plant, its seeds, or extracts);
- 20 (27) N-ethyl-3-piperidyl benzilate;
- 21 (28) N-methyl-3-piperidyl benzilate;
- 22 (29) psilocybin;
- 23 (30) psilocyn;
- 24 (31) tetrahydrocannabinols;



- 1 (32) ethylamine analog of phencyclidine (N-ethyl-1-  
2 phenylcyclohexylamine);
- 3 (33) pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-  
4 pyrrolidine);
- 5 (34) thiophene analog of phencyclidine (1-[1-(2-thienyl)-cyclohexyl]-  
6 piperidine);
- 7 (35) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 8 (36) 4-methylmethcathinone (mephedrone);
- 9 (37) 3, 4-methylenedioxypropylvalerone (MDPV);
- 10 (38) 2-(2,5-dimethoxy-4-ethylphenyl) ethanamine (2C-E);
- 11 (39) 2-(2,5-dimethoxy-4-methylphenyl) ethanamine (2C-D);
- 12 (40) 2-(4-chloro-2,5-dimethoxyphenyl) ethanamine (2C-C);
- 13 (41) 2-(4-iodo-2,5-dimethoxyphenyl) ethanamine (2C-I);
- 14 (42) 2-[4-(ethylthio)-2,5-dimethoxyphenyl] ethanamine (2C-T-2);
- 15 (43) 2-[4-(isopropylthio)-2,5-dimethoxyphenyl] ethanamine (2C-T-4);
- 16 (44) 2-(2,5-dimethoxyphenyl) ethanamine (2C-H);
- 17 (45) 2-(2,5-dimethoxy-4-nitro-phenyl) ethanamine (2C-N);
- 18 (46) 2-(2,5-dimethoxy-4-(n)-propylphenyl) ethanamine (2C-P);
- 19 (47) 3,4-methylenedioxy-N-methylcathinone (methydone);
- 20 (48) (1-pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone  
21 (UR-144);
- 22 (49) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)  
23 methanone (5-fluoro-UR-144, XLR11);
- 24 (50) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA,  
25 AKB48);
- 26 (51) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-22);

- 1 (52) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-  
2 PB-22);
- 3 (53) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-  
4 indazole-3-carboxamide (AB-FUBINACA);
- 5 (54) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-  
6 indazole-3-carboxamide (ADB-PINACA);
- 7 (55) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine  
8 (25I-NBOMe);
- 9 (56) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine  
10 (25C-NBOMe);
- 11 (57) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine  
12 (25B-NBOMe);
- 13 (58) marijuana extract (meaning an extract containing one or more  
14 cannabinoids that has been derived from any plant of the genus cannabis, other than the  
15 separated resin, whether crude or purified, obtained from the plant);
- 16 (59) 4-methyl-N-ethylcathinone (4-MEC);
- 17 (60) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
- 18 (61) alpha-pyrrolidinopentiophenone (alpha-PVP);
- 19 (62) 1-(1,3-benzodioxol-5-yl)-2-(methylamino) butan-1-one (butylone);
- 20 (63) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
- 21 (64) 1-(1,3-benzodioxol-5-yl)-2-(methylamino) pentan-1-one (pentylone);
- 22 (65) 4-fluoro-N-methylcathinone (flephedrone);
- 23 (66) 3-fluoro-N-methylcathinone (3-FMC);
- 24 (67) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone);
- 25 (68) alpha-pyrrolidinobutiophenone (alpha-PBP);
- 26 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-  
27 indazole-3-carboxamide (AB-CHMINACA);
- 28 (70) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-  
29 carboxamide (AB-PINACA);

1 (71) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone  
2 (THJ-2201); and

3 (72) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-  
4 1H-indazole-3-carboxamide (MAB-CHMINACA).

5 (e) Unless specifically excepted under this subtitle or listed in another schedule,  
6 a material, compound, mixture, or preparation that contains any quantity of the following  
7 substances having depressant effects on the central nervous system, or that contains its  
8 salts, isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts of  
9 isomers is possible within the specific chemical designation, is a substance listed in  
10 Schedule I:

11 (1) gamma-hydroxybutyric acid (GHB);

12 (2) mecloqualone; and

13 (3) methaqualone.

14 (f) Unless specifically excepted or listed in another schedule, any material,  
15 compound, mixture, or preparation that contains any quantity of the following substances  
16 having a stimulant effect on the central nervous system, or that contains its salts, isomers,  
17 or salts of isomers, is a substance listed in Schedule I:

18 (1) aminorex;

19 (2) N-benzylpiperazine (BZP);

20 (3) cathinone;

21 (4) fenethylamine;

22 (5) methcathinone;

23 (6) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-  
24 oxazolamine);

25 (7) N-ethylamphetamine; and

26 (8) N, N-dimethylamphetamine.

27 (g) Unless specifically excepted under this subtitle or listed in another schedule,  
28 any material, compound, mixture, or preparation that contains any quantity of the  
29 following substances, or that contains their salts, isomers, or salts of isomers, whenever the  
30 existence of such salts, isomers, or salts of isomers is possible within the specific chemical  
31 designation, is a substance listed in Schedule I:

- 1                   (1)    5-(1,     1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol  
2 (CP-47,497);
- 3                   (2)    5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-  
4 47,497 C8 homolog);
- 5                   (3)    1-pentyl-3-(1-naphthoyl) indole (JWH-018 and AM678);
- 6                   (4)    1-butyl-3-(1-naphthoyl) indole (JWH-073);
- 7                   (5)    1-hexyl-3-(1-naphthoyl) indole (JWH-019);
- 8                   (6)    1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl) indole (JWH-200);
- 9                   (7)    1-pentyl-3-(2-methoxyphenylacetyl) indole (JWH-250);
- 10                  (8)    1-pentyl-3-[1-(4-methoxynaphthoyl)] indole (JWH-081);
- 11                  (9)    1-pentyl-3-(4-methyl-1-naphthoyl) indole (JWH-122);
- 12                  (10)  1-pentyl-3-(4-chloro-1-naphthoyl) indole (JWH-398);
- 13                  (11)  1-(5-fluoropentyl)-3-(1-naphthoyl) indole (AM2201);
- 14                  (12)  1-(5-fluoropentyl)-3-(2-iodobenzoyl) indole (AM694);
- 15                  (13)  1-pentyl-3-[(4-methoxy)-benzoyl] indole (SR-19 and RCS-4);
- 16                  (14)  1-cyclohexylethyl-3-(2-methoxyphenylacetyl) indole 7008 (SR-18 and  
17 RCS-8); and
- 18                  (15)  1-pentyl-3-(2-chlorophenylacetyl) indole (JWH-203).

- 19           (h) (B)   (1)    In this subsection:
- 20                   (i)    “controlled dangerous substance analogue” means a substance:
- 21                           1.    that has a chemical structure substantially similar to the  
22 chemical structure of a controlled dangerous substance [listed] **DESCRIBED** in Schedule I  
23 or Schedule II; and
- 24                           2.    that has a stimulant, depressant, or hallucinogenic effect  
25 on the central nervous system that is substantially similar to or greater than the stimulant,  
26 depressant, or hallucinogenic effect on the central nervous system of a controlled dangerous  
27 substance [listed] **DESCRIBED** in Schedule I or Schedule II; but

1 (ii) “controlled dangerous substance analogue” does not include:

2 1. a controlled dangerous substance;

3 2. a substance for which there is an approved new drug  
4 application; or

5 3. a substance exempted for investigational use under § 506  
6 of the Federal Food, Drug, and Cosmetic Act.

7 (2) To the extent intended for human consumption, each controlled  
8 dangerous substance analogue is a substance [listed] DESCRIBED in Schedule I.

9 [(i)] (C) The Department may not add a substance to Schedule I under § 5–202  
10 of this title unless the Department finds:

11 (1) a high potential for abuse of the substance;

12 (2) no accepted medical use in the United States for the substance; and

13 (3) a lack of accepted safety for use of the substance under medical  
14 supervision.

15 5–403.

16 (a) Schedule II consists of each controlled dangerous substance:

17 [(1)] listed in this section;

18 [(2)] (1) added to Schedule II by the Department under § 5–202(b) of this  
19 title; or

20 [(3)] (2) designated as a Schedule II controlled dangerous substance by  
21 the federal government unless the Department objects under § 5–202(f) of this title.

22 [(b)] Unless specifically excepted or unless listed in another schedule, any of the  
23 following substances whether produced directly or indirectly by extraction from substances  
24 of vegetable origin, or independently by means of chemical synthesis, or by a combination  
25 of extraction and chemical synthesis:

26 (1) opium and opiate, and any salt, compound, derivative, or preparation  
27 of opium or opiate excluding apomorphine, thebaine–derived butorphanol, dextrorphan,  
28 nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, and naltrexone, and their  
29 respective salts, but including the following:

30 (i) codeine;

- 1 (ii) dihydroetorphine;
- 2 (iii) ethylmorphine;
- 3 (iv) etorphine hydrochloride;
- 4 (v) granulated opium;
- 5 (vi) hydrocodone;
- 6 (vii) hydromorphone;
- 7 (viii) metopon;
- 8 (ix) morphine;
- 9 (x) opium extracts;
- 10 (xi) opium fluid;
- 11 (xii) oripavine;
- 12 (xiii) oxycodone;
- 13 (xiv) oxymorphone;
- 14 (xv) powdered opium;
- 15 (xvi) raw opium;
- 16 (xvii) thebaine; and
- 17 (xviii) tincture of opium;
- 18 (2) any salt, compound, derivative, or preparation thereof which is  
19 chemically equivalent or identical with any of the substances referred to in item (1) of this  
20 subsection, except that these substances may not include the isoquinoline alkaloids of  
21 opium;
- 22 (3) opium poppy and poppy straw;
- 23 (4) coca leaves and any salt, compound, derivative, or preparation of coca  
24 leaves, including cocaine and ecgonine and their salts, isomers, derivatives and salts of  
25 isomers and derivatives, and any salt, compound, derivative, or preparation thereof which  
26 is chemically equivalent or identical with any of these substances, except that the  
27 substances may not include:

1 (i) decocainized coca leaves or extraction of coca leaves, which  
2 extractions do not contain cocaine or ecgonine; or

3 (ii) ioflupane; and

4 (5) concentrate of poppy straw (the crude extract of poppy straw in either  
5 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium  
6 poppy).

7 (c) Unless specifically excepted or unless in another schedule any of the following  
8 opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers  
9 whenever the existence of such isomers, esters, ethers, and salts is possible within the  
10 specific chemical designation, dextrophan and levopropoxyphene excepted:

11 (1) alfentanil;

12 (2) alphaprodine;

13 (3) anileridine;

14 (4) bezitramide;

15 (5) bulk dextropropoxyphene (non-dosage forms);

16 (6) carfentanil;

17 (7) dihydrocodeine;

18 (8) diphenoxylate;

19 (9) fentanyl;

20 (10) isomethadone;

21 (11) levo-alphaacetylmethadol;

22 (12) levomethorphan;

23 (13) levorphanol;

24 (14) metazocine;

25 (15) methadone;

26 (16) methadone – intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl  
27 butane;

1 (17) moramide – intermediate, 2-methyl-3-morpholino-1, 1-  
2 diphenylpropane-carboxylic acid;

3 (18) pethidine (meperidine);

4 (19) pethidine – intermediate – A, 4-cyano-1-methyl-4-phenylpiperidine;

5 (20) pethidine – intermediate – B, ethyl-4-phenylpiperidine-4-carboxylate;

6 (21) pethidine – intermediate – C, 1-methyl-4-phenylpiperidine-4-  
7 carboxylic acid;

8 (22) phenazocine;

9 (23) piminodine;

10 (24) racemethorphan;

11 (25) racemorphan;

12 (26) remifentanyl;

13 (27) sulfentanyl;

14 (28) tapentadol; and

15 (29) thiafentanyl.

16 (d) Unless specifically excepted under this subtitle or listed in another schedule,  
17 a substance is listed in Schedule II if the substance includes a material, compound, mixture,  
18 or preparation that contains any quantity of the following substances having a potential  
19 for abuse associated with a stimulant effect on the central nervous system:

20 (1) amphetamine, its salts, optical isomers, and salts of its optical isomers;

21 (2) methamphetamine, its salts, isomers, and salts of isomers;

22 (3) phenmetrazine and its salts;

23 (4) methylphenidate; and

24 (5) lisdexamfetamine, its salts, isomers, and salts of isomers.

25 (e) Unless specifically excepted under this subtitle or listed in another schedule,  
26 a substance is listed in Schedule II if the substance includes a material, compound, mixture,  
27 or preparation that contains any quantity of the following substances having a depressant



1 effect on the central nervous system, including its salts, isomers, and salts of isomers  
2 whenever the existence of such salts, isomers, and salts of isomers is possible within the  
3 specific chemical designation:

- 4 (1) amobarbital;
- 5 (2) glutethimide;
- 6 (3) pentobarbital;
- 7 (4) phencyclidine; and
- 8 (5) secobarbital.

9 (f) As listed in Schedule II under Title 21 of the Code of Federal Regulations:

- 10 (1) nabilone; and
- 11 (2) dronabinol [(–)-delta-9-trans tetrahydrocannabinol] in an oral  
12 solution in a drug product approved for marketing by the United States Food and Drug  
13 Administration.

14 (g) Unless specifically excepted or unless listed in another schedule, any material,  
15 compound, mixture, or preparation which contains any quantity of the following  
16 substances:

- 17 (1) immediate precursor to amphetamine and methamphetamine:
  - 18 (i) phenylacetone; and
  - 19 (ii) reserved;
- 20 (2) immediate precursors to phencyclidine (PCP):
  - 21 (i) 1-phenylcyclohexylamine; and
  - 22 (ii) 1-piperidinocyclohexanecarbonitrile (PCC); and
- 23 (3) immediate precursor to fentanyl:
  - 24 (i) 4-anilino-N-phenethylpiperidine (ANPP); and
  - 25 (ii) reserved.

26 (h) **(B)** The Department may not add a substance to Schedule II under § 5–202  
27 of this title unless the Department finds:

1 (1) a high potential for abuse of the substance;

2 (2) currently accepted medical use of the substance in the United States,  
3 or currently accepted medical use with severe restrictions; and

4 (3) evidence that abuse of the substance may lead to severe psychological  
5 or physical dependence.

6 5–404.

7 (a) Schedule III consists of each controlled dangerous substance by whatever  
8 official name, common or usual name, chemical name, or brand name [designated]:

9 [(1) listed in this section;

10 (2)] (1) added to Schedule III by the Department under § 5–202(b) of this  
11 title; or

12 [(3)] (2) designated as a Schedule III controlled dangerous substance by  
13 the federal government unless the Department objects under § 5–202(f) of this title.

14 [(b) (1) Unless specifically excepted or listed in another schedule, a substance  
15 is listed in Schedule III if the substance includes a material, compound, mixture, or  
16 preparation that contains any quantity of the following substances having a stimulant  
17 effect on the central nervous system:

18 (i) those compounds, mixtures, or preparations in dosage unit form  
19 containing any stimulant substances listed in Schedule II, which compounds, mixtures, or  
20 preparations were listed on August 25, 1971, as excepted compounds under § 1308.32 of the  
21 Code of Federal Regulations, and any other drug of the quantitative composition shown in  
22 that list for those drugs or that is the same except that it contains a lesser quantity of  
23 controlled substances;

24 (ii) benzphetamine;

25 (iii) chlorphentermine;

26 (iv) clortermine; and

27 (v) phendimetrazine.

28 (2) Subject to paragraph (3) of this subsection, substances in Schedule III  
29 include:

30 (i) a salt of a substance listed in this subsection;

1 (ii) an optical, position, or geometric isomer of a substance listed in  
2 this subsection; or

3 (iii) a salt of an isomer of a substance listed in this subsection.

4 (3) Unless listed in another schedule, a salt, isomer, or salt of an isomer  
5 described in paragraph (2) of this subsection may be included in Schedule III only if the  
6 existence of the salts, isomers, and salts of isomers is possible within the specific chemical  
7 designation.

8 (c) Unless listed in another schedule, a substance is listed in Schedule III if the  
9 substance includes a material, compound, mixture, or preparation that contains any  
10 quantity of the following substances having a potential for abuse associated with a  
11 depressant effect on the central nervous system:

12 (1) any compound, mixture, or preparation containing:

13 (i) amobarbital;

14 (ii) secobarbital;

15 (iii) pentobarbital; or

16 (iv) any salt thereof and one or more other active medicinal  
17 ingredients that are not listed in any schedule;

18 (2) any suppository dosage form containing:

19 (i) amobarbital;

20 (ii) secobarbital;

21 (iii) pentobarbital; or

22 (iv) any salt of any of these drugs and approved by the U.S. Food and  
23 Drug Administration for marketing only as a suppository;

24 (3) except those substances that are specifically listed in other schedules,  
25 a substance that contains any quantity of a derivative of barbituric acid, a salt of a  
26 derivative of a barbituric acid, or butalbital, including, with one or more active, nonnarcotic  
27 ingredients in recognized therapeutic amounts, (Fioricet) and (Fiorinal);

28 (4) chlorhexadol;

29 (5) embutramide;

1 (6) any drug product containing gamma hydroxybutyric acid, including its  
2 salts, isomers, and salts of isomers, for which an application is approved under Section 505  
3 of the Federal Food, Drug, and Cosmetic Act;

4 (7) ketamine, its salts, isomers, and salts of isomers;

5 (8) lysergic acid;

6 (9) lysergic acid amide;

7 (10) methyprylon;

8 (11) perampanel, and its salts, isomers, and salts of isomers (FYCOMPA);

9 (12) sulfondiethylmethane;

10 (13) sulfonethylmethane;

11 (14) sulfonmethane; and

12 (15) tiletamine and zolazepam or any salt thereof, including a tiletamine-  
13 zolazepam combination product (trade name Telazol).

14 (d) As listed in Schedule III under Title 21 of the Code of Federal Regulations,  
15 nalorphine 9400.

16 (e) Unless specifically excepted or unless listed in another schedule:

17 (1) substances listed in Schedule III include any material, compound,  
18 mixture, or preparation containing any of the following narcotic drugs, or their salts  
19 calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

20 (i) not more than 1.80 grams of codeine per 100 milliliters or not  
21 more than 90 milligrams per dosage unit, with an equal or greater quantity of an  
22 isoquinoline alkaloid of opium;

23 (ii) not more than 1.80 grams of codeine per 100 milliliters or not  
24 more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients  
25 in recognized therapeutic amounts;

26 (iii) not more than 1.80 grams of dihydrocodeine per 100 milliliters  
27 or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic  
28 ingredients in recognized therapeutic amounts;

29 (iv) not more than 300 milligrams of ethylmorphine per 100  
30 milliliters or not more than 15 milligrams per dosage unit, with one or more active,  
31 nonnarcotic ingredients in recognized therapeutic amounts;

1 (v) not more than 500 milligrams of opium per 100 milliliters or per  
2 100 grams, or not more than 25 milligrams per dosage unit, with one or more active,  
3 nonnarcotic ingredients in recognized therapeutic amounts;

4 (vi) not more than 100 milligrams of opium per 100 milliliters or per  
5 100 grams, or not more than 5 milligrams per dosage unit; and

6 (vii) not more than 50 milligrams of morphine per 100 milliliters or  
7 per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic  
8 amounts.

9 (2) any material, compound, mixture, or preparation containing any of the  
10 following narcotic drugs or their salts, as set forth below:

11 (i) buprenorphine; and

12 (ii) reserved.

13 (3) if not combined with one or more active medicinal ingredients that are  
14 listed in another schedule, substances listed in Schedule III include a suppository dosage  
15 form or salt of a suppository dosage that contains:

16 (i) amobarbital;

17 (ii) secobarbital; or

18 (iii) pentobarbital.

19 (f) (1) Except as provided in paragraph (2) of this subsection, an anabolic  
20 steroid consisting of any material, compound, mixture, or preparation containing any  
21 quantity of the following substances, including its salts, esters, and ethers:

22 (i) 3beta,17-dihydroxy-5a-androstane;

23 (ii) 3alpha,17beta-dihydroxy-5a-androstane;

24 (iii) 5 alpha-androstan-3,17-dione;

25 (iv) 1-androstenediol (3beta,17beta-dihydroxy-5alpha-androst-1-  
26 ene);

27 (v) 1-androstenediol (3alpha,17beta-dihydroxy-5alpha-androst-  
28 1-ene);

29 (vi) 4-androstenediol (3beta,17beta-dihydroxy-androst-4-ene);

- 1 (vii) 5-androstenediol (3beta,17beta-dihydroxy-androst-5-ene);
- 2 (viii) 1-androstenedione;
- 3 (ix) 4-androstenedione;
- 4 (x) 5-androstenedione;
- 5 (xi) bolasterone;
- 6 (xii) boldenone;
- 7 (xiii) boldione;
- 8 (xiv) calusterone;
- 9 (xv) chlorotestosterone (clostebol);
- 10 (xvi) dehydrochloromethyltestosterone;
- 11 (xvii) desoxymethyltestosterone;
- 12 (xviii) delta1-dihydrotestosterone (17beta-hydroxy-5alpha-androst-  
13 1-en-3-one);
- 14 (xix) dihydrotestosterone (4-dihydrotestosterone) (17beta-hydroxy-  
15 androstan-3-one) (stanolone);
- 16 (xx) drostanolone;
- 17 (xxi) ethylestrenol;
- 18 (xxii) fluoxymesterone;
- 19 (xxiii) formebolone;
- 20 (xxiv) furazabol;
- 21 (xxv) 13beta-ethyl-17beta-hydroxygon-4-en-3-one;
- 22 (xxvi) 4-hydroxytestosterone;
- 23 (xxvii) 4-hydroxy-19-nortestosterone;
- 24 (xxviii) mestanolone (17alpha-methyl-17beta-hydroxy-5-  
25 androstan-3-one);

- 1 (xxix) mesterolone;
- 2 (xxx) methandienone (methandrostenolone) (17alpha-methyl-  
3 17beta-hydroxyandrost-1,4-dien-3-one);
- 4 (xxxi) methandriol;
- 5 (xxxii) methasterone;
- 6 (xxxiii) methenolone;
- 7 (xxxiv) 17alpha-methyl-3beta, 17beta-dihydroxy-5a-  
8 androstane;
- 9 (xxxv) 17alpha-methyl-3alpha, 17beta-dihydroxy-5a-androstane;
- 10 (xxxvi) 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4-ene;
- 11 (xxxvii) 17alpha-methyl-4-hydroxynandrolone;
- 12 (xxxviii) methyldienolone;
- 13 (xxxix) methyltrienolone;
- 14 (xl) methyltestosterone;
- 15 (xli) mibolerone;
- 16 (xlii) 17alpha-methyl-delta1-dihydrotestosterone;
- 17 (xliii) nandrolone;
- 18 (xliv) 19-nor-4-androstenediol (3beta, 17beta-dihydroxyestr-4-ene);
- 19 (xlv) 19-nor-4-androstenediol (3alpha, 17beta-dihydroxyestr-4-  
20 ene);
- 21 (xlvi) 19-nor-5-androstenediol (3beta, 17beta-dihydroxyestr-5-ene);
- 22 (xlvii) 19-nor-5-androstenediol (3alpha, 17beta-dihydroxyestr-5-  
23 ene);
- 24 (xlviii) 19-nor-4,9(10)-androstadienedione;
- 25 (xlix) 19-nor-4-androstenedione;
- 26 (l) 19-nor-5-androstenedione;

- 1 (li) norbolethone (13beta, 17alpha–diethyl–17beta–hydroxygon–4–  
 2 en–3–one);
- 3 (lii) norclostebol;
- 4 (liii) norethandrolone;
- 5 (liv) normethandrolone;
- 6 (lv) oxandrolone;
- 7 (lvi) oxymesterone;
- 8 (lvii) oxymetholone;
- 9 (lviii) prostanazol;
- 10 (lix) stanozolol;
- 11 (lx) stenbolone;
- 12 (lxi) testolactone;
- 13 (lxii) testosterone;
- 14 (lxiii) tetrahydrogestrinone; and
- 15 (lxiv) trenbolone.

16 (2) The following substances are not included in Schedule III:

- 17 (i) an estrogen, progestin, or corticosteroid; or
- 18 (ii) a substance covered by paragraph (1) of this subsection if:
- 19 1. expressly intended for administration through implants to  
 20 cattle or other nonhuman species; and
- 21 2. approved for that use by the U.S. Food and Drug  
 22 Administration.

23 (g) Hallucinogenic substances include:

- 24 (1) dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin  
 25 capsule in a U.S. Food and Drug Administration–approved product; and



1 (2) reserved.

2 (h) **(B)** The Department may not add a substance to Schedule III under §  
3 5–202 of this title unless the Department finds:

4 (1) a potential for abuse of the substance that is less than that for the  
5 substances listed in Schedule I and Schedule II;

6 (2) well documented and approved medical use of the substance in the  
7 United States; and

8 (3) evidence that abuse of the substance may lead to moderate or low  
9 physical dependence or high psychological dependence.

10 5–405.

11 (a) Schedule IV consists of each controlled dangerous substance:

12 [(1) listed in this section;

13 (2) **(1)** added to Schedule IV by the Department under § 5–202(b) of this  
14 title; or

15 [(3) **(2)** designated as a Schedule IV controlled dangerous substance by  
16 the federal government unless the Department objects under § 5–202(f) of this title.

17 **(b)** Unless specifically excepted or unless listed in another schedule, any material,  
18 compound, mixture, or preparation containing any of the following narcotic drugs, or their  
19 salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth  
20 below:

21 (1) not more than 1 milligram of difenoxin and not less than 25 micrograms  
22 of atropine sulfate per dosage unit;

23 (2) dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-  
24 methyl-2-propionoxybutane); and

25 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its  
26 salts, optical and geometric isomers and salts of these isomers (including tramadol).

27 (c) Substances listed in Schedule IV include a material, compound, mixture, or  
28 preparation that contains any quantity of the following substances having a potential for  
29 abuse associated with a depressant effect on the central nervous system, including its salts,  
30 isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of  
31 isomers is possible within the specific chemical designations:

32 (1) alfaxalone;

- 1 (2) alprazolam;
- 2 (3) barbital;
- 3 (4) brexanolone;
- 4 (5) bromazepam;
- 5 (6) camazepam;
- 6 (7) carisoprodol;
- 7 (8) chloral betaine;
- 8 (9) chloral hydrate;
- 9 (10) chlordiazepoxide;
- 10 (11) clobazam;
- 11 (12) clonazepam;
- 12 (13) clorazepate;
- 13 (14) clotiazepam;
- 14 (15) cloxazolam;
- 15 (16) delorazepam;
- 16 (17) diazepam;
- 17 (18) dichloralphenazone;
- 18 (19) estazolam;
- 19 (20) ethchlorvynol;
- 20 (21) ethinamate;
- 21 (22) ethyl loflazepate;
- 22 (23) fludiazepam;
- 23 (24) flunitrazepam;

- 1 (25) flurazepam;
- 2 (26) fospropofol;
- 3 (27) halazepam;
- 4 (28) haloxazolam;
- 5 (29) ketazolam;
- 6 (30) lorazepam;
- 7 (31) lorazepam;
- 8 (32) lormetazepam;
- 9 (33) mebutamate;
- 10 (34) medazepam;
- 11 (35) meprobamate;
- 12 (36) methohexital;
- 13 (37) methylphenobarbital (mephobarbital);
- 14 (38) midazolam;
- 15 (39) nimetazepam;
- 16 (40) nitrazepam;
- 17 (41) nordiazepam;
- 18 (42) oxazepam;
- 19 (43) oxazolam;
- 20 (44) paraldehyde;
- 21 (45) petrichloral;
- 22 (46) phenobarbital;
- 23 (47) pinazepam;
- 24 (48) prazepam;

- 1 (49) quazepam;
- 2 (50) suvorexant (Belsomra);
- 3 (51) temazepam;
- 4 (52) tetrazepam;
- 5 (53) triazolam;
- 6 (54) zaleplon (Sonata);
- 7 (55) zolpidem (Ambien); and
- 8 (56) zopiclone (Lunesta).

9 (d) Substances listed in Schedule IV include:

- 10 (1) a material, compound, mixture, or preparation that contains  
11 fenfluramine; and
- 12 (2) if its existence is possible:
- 13 (i) a salt of fenfluramine;
- 14 (ii) an optical, position, or geometric isomer of fenfluramine,  
15 including dexfenfluramine; and
- 16 (iii) a salt of an isomer of fenfluramine.

17 (e) Substances listed in Schedule IV include:

- 18 (1) a material, compound, mixture, or preparation that contains lorcaserin;  
19 and
- 20 (2) if its existence is possible:
- 21 (i) a salt of lorcaserin;
- 22 (ii) an optical, position, or geometric isomer of lorcaserin; and
- 23 (iii) a salt of an isomer of lorcaserin.

24 (f) Substances listed in Schedule IV include a material, compound, mixture, or  
25 preparation that contains any quantity of the following substances having a potential for

1 abuse associated with a stimulant effect on the central nervous system, including its salts,  
2 isomers, and salts of isomers:

3 (1) cathine ((+)-norpseudoephedrine);

4 (2) diethylpropion;

5 (3) fencamfamin;

6 (4) fenproporex;

7 (5) mazindol;

8 (6) mefenorex;

9 (7) modafinil;

10 (8) pemoline, including organometallic complexes and their chelates;

11 (9) phentermine;

12 (10) pipradrol;

13 (11) sibutramine;

14 (12) solriamfetol (2-amino-3-phenylpropyl carbamate; benzenepropanol,  
15 beta-amino-, carbamate (ester)); and

16 (13) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

17 (g) Unless specifically excepted or unless listed in another schedule, any material,  
18 compound, mixture, or preparation that contains any quantity of the following substances,  
19 including its salts:

20 (1) pentazocine;

21 (2) butorphanol (including its optical isomers); and

22 (3) eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl]-2, 6-  
23 dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-  
24 yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its  
25 salts, isomers, and salts of isomers.

26 (h) By regulation, the Department may exempt from this section a compound,  
27 mixture, or preparation that contains a depressant substance listed in subsection (c) of this  
28 section if:

1 (1) the compound, mixture, or preparation contains an active medicinal  
2 ingredient that does not have a depressant effect on the central nervous system; and

3 (2) the admixtures are included in combinations, quantity, proportion, or  
4 concentration that vitiate the potential for abuse of the substances that have a depressant  
5 effect on the central nervous system.

6 (i) **(B)** The Department may not add a substance to Schedule IV under §  
7 5–202 of this title unless the Department finds that:

8 (1) the substance has a low potential for abuse relative to the substances  
9 listed in Schedule III;

10 (2) the substance has currently accepted medical use in treatment in the  
11 United States; and

12 (3) abuse of the substance may lead to limited physical dependence or  
13 psychological dependence relative to the substances in Schedule III.

14 5–406.

15 (a) Schedule V consists of each controlled dangerous substance:

16 [(1) listed in this section;

17 (2)] **(1)** added to Schedule V by the Department under § 5–202(b) of this  
18 title; or

19 [(3)] **(2)** designated as a Schedule V controlled dangerous substance by  
20 the federal government unless the Department objects under § 5–202(f) of this title.

21 [(b) Unless specifically excepted or unless listed in another schedule, any material,  
22 compound, mixture, or preparation containing any of the following narcotic drugs and their  
23 salts, as set forth below:

24 (1) reserved; and

25 (2) reserved.

26 (c) Any compound, mixture, or preparation containing any of the following  
27 narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited  
28 quantities as set forth below, which shall include one or more nonnarcotic active medicinal  
29 ingredients in sufficient proportion to confer upon the compound, mixture, or preparation  
30 valuable medicinal qualities other than those possessed by narcotic drugs alone:

31 (1) not more than 200 milligrams of codeine per 100 milliliters or per 100  
32 grams;

1 (2) not more than 100 milligrams of dihydrocodeine per 100 milliliters or  
2 per 100 grams;

3 (3) not more than 100 milligrams of ethylmorphine per 100 milliliters or  
4 per 100 grams;

5 (4) not more than 2.5 milligrams of diphenoxylate and not less than 25  
6 micrograms of atropine sulfate per dosage unit; or

7 (5) difenoxin preparations 0.5mg/25ug ATSO4/DU (MOTOFEN).

8 (d) Unless specifically exempted or excluded or unless listed in another schedule,  
9 any material, compound, mixture, or preparation that contains any quantity of the  
10 following substances having a stimulant effect on the central nervous system, including its  
11 salts, isomers, and salts of isomers:

12 (1) pyrovalerone; and

13 (2) reserved.

14 (e) Unless specifically exempted or excluded or unless listed in another schedule,  
15 any material, compound, mixture, or preparation that contains any quantity of the  
16 following substances having a depressant effect on the central nervous system, including  
17 its salts:

18 (1) brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]  
19 butanamide) (Briviact);

20 (2) ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic  
21 acid ethyl ester] (Potiga);

22 (3) lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide]  
23 (Vimpat); and

24 (4) pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid] (Lyrica).

25 (f) A drug product in finished dosage formulation that has been approved by the  
26 United States Food and Drug Administration that contains cannabidiol (2-[1R-3-methyl-  
27 6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from  
28 cannabis and no more than 0.1% (w/w) residual tetrahydrocannabinols.

29 (g) (B) The Department may not add a substance to Schedule V under § 5-202  
30 of this title unless the Department finds:

31 (1) the substance has a low potential for abuse relative to the substances  
32 listed in Schedule IV;

1 (2) the substance has currently accepted medical use in the United States;  
2 and

3 (3) abuse of the substance may lead to limited physical dependence or  
4 psychological dependence liability relative to the substances listed in Schedule IV.

5 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June  
6 1, 2022.

Approved:

\_\_\_\_\_  
Governor.

\_\_\_\_\_  
Speaker of the House of Delegates.

\_\_\_\_\_  
President of the Senate.